Dihydroartemisinin-piperaquine versus chloroquine in the treatment of plasmodium vivax malaria in Thailand: A randomized controlled trial

Clinical Infectious Diseases

Volumn 53, Issue 10, 2011, Pages 977-984

  Phyo, Aung Pyae ^a   Lwin, Khin Maung ^a   Price, Ric N ^c,d   Ashley, Elizabeth A ^a,b,d   Russell, Bruce ^e   Sriprawat, Kanlaya ^a   Lindegardh, Niklas ^b,d   Singhasivanon, Pratap ^b   White, Nicholas J ^b   Nosten, François ^a,b  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DUOCOTEXIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; CHILD; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; PARASITE CLEARANCE; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; REVIEW; SCHOOL CHILD; THAILAND;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; FEMALE; HUMANS; INFANT; MALARIA, VIVAX; MALE; MIDDLE AGED; PARASITIC SENSITIVITY TESTS; PLASMODIUM VIVAX; QUINOLINES; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054767617     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir631     Document Type: Review

References (25)

1. Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004; 48:4075-83. (Pubitemid 39434858)
2. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010; 10:405-16.
3. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet 1989; 2:1183-4. (Pubitemid 19275451)
4. Baird JK, Basri H, Purnomo , et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 1991; 44:547-52.
5. Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: An open-label randomised comparison. Lancet 2007; 369:757-65. (Pubitemid 46335820)
6. Sumawinata IW, Bernadeta , Leksana B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 2003; 68: 416-20. (Pubitemid 38230641)
7. Guthmann JP, Pittet A, Lesage A, et al. Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Trop Med Int Health 2008; 13:91-8. (Pubitemid 351271394)
8. Marlar T, Myat Phone K, Aye Yu S, Khaing Khaing G, Ma S, Myint O. Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Trans R Soc Trop Med Hyg 1995; 89:307-8.
9. Lee KS, Kim TH, Kim ES, et al. Short report: Chloroquine-resistant Plasmodium vivax in the Republic of Korea. Am J Trop Med Hyg 2009; 80:215-7.
10. Kurcer MA, Simsek Z, Zeyrek FY, et al. Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey. Ann Trop Med Parasitol 2004; 98:447-51. (Pubitemid 38951677)
11. Teka H, Petros B, Yamuah L, et al. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J 2008; 7:220.
12. de Santana Filho FS, Arcanjo AR, Chehuan YM, et al. Chloroquineresistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis 2007; 13:1125-6. (Pubitemid 47048104)
13. Luxemburger C, van Vugt M, Jonathan S, et al. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg 1999; 93:433-8. (Pubitemid 29405879)
14. Suwanarusk R, Russell B, Chavchich M, et al. Chloroquine resistant Plasmodium vivax: In vitro characterisation and association with molecular polymorphisms. PLoS One 2007; 2:e1089.
15. Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008; 359:2545-7.
16. Luxemburger C, Thwai KL, White NJ, et al. The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg 1996; 90:105-11. (Pubitemid 26141072)
17. Pukrittayakamee S, Chantra A, Simpson JA, et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 2000; 44:1680-5. (Pubitemid 30340814)
18. Blessborn D, Neamin G, Bergqvist Y, Lindegardh N. A new approach to evaluate stability of amodiaquine and its metabolite in blood and plasma. J Pharm Biomed Anal 2006; 41:207-12.
19. Berliner RW, Earle DP, Taggart JV, et al. Studies on the chemotherapy of the human malarias. Vi. The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline. J Clin Invest 1948; 27:98-107.
20. Guerra CA, Howes RE, Patil AP, et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis 2010; 4:e774.
21. White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol 2002; 18:458-64.
22. Hasugian AR, Purba HL, Kenangalem E, et al. Dihydroartemisininpiperaquine versus artesunate-amodiaquine: Superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 2007; 44: 1067-74. (Pubitemid 46580274)
23. Karunajeewa H, Lim C, Hung TY, et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol 2004; 57:93-9. (Pubitemid 38067955)
24. Sharrock WW, Suwanarusk R, Lek-Uthai U, et al. Plasmodium vivax trophozoites insensitive to chloroquine. Malar J 2008; 7:94.
25. Muhamad P, Ruengweerayut R, Chacharoenkul W, Rungsihirunrat K, Na-Bangchang K. Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010. Malar J 2011; 10:44.